|
gptkbp:instance_of
|
gptkb:healthcare_organization
|
|
gptkbp:affects
|
plasma cells
|
|
gptkbp:clinical_trial
|
ongoing
|
|
gptkbp:current_use
|
gptkb:healthcare_organization
infections
osteoporosis
|
|
gptkbp:end_of_life
|
varies by treatment
generally lower than newly diagnosed
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
relapsed or refractory multiple myeloma
|
|
gptkbp:is_a
|
gptkb:healthcare_organization
|
|
gptkbp:is_characterized_by
|
increased levels of monoclonal protein
|
|
gptkbp:is_involved_in
|
gptkb:stock_market_index
|
|
gptkbp:population
|
gptkb:Educational_Institution
counseling services
financial assistance programs
|
|
gptkbp:research_focus
|
biomarkers
genetic factors
new therapies
|
|
gptkbp:risk_factor
|
age
obesity
family history
exposure to radiation
|
|
gptkbp:social_responsibility
|
varies by individual
|
|
gptkbp:symptoms
|
gptkb:fandom
fatigue
blood tests
imaging studies
bone pain
bone marrow biopsy
hypercalcemia
|
|
gptkbp:treatment
|
gptkb:venetoclax
gptkb:carfilzomib
gptkb:vaccine
gptkb:bortezomib
gptkb:lenalidomide
gptkb:thalidomide
gptkb:dexamethasone
gptkb:pomalidomide
chemotherapy
symptom management
remission
stem cell transplant
daratumumab
elotuzumab
allogeneic stem cell transplant
autologous stem cell transplant
isatuximab
selinexor
|
|
gptkbp:bfsParent
|
gptkb:Pomalidomide
gptkb:Carfilzomib
gptkb:CYAD-101
gptkb:lenalidomide
gptkb:Kyprolis
gptkb:pomalidomide
|
|
gptkbp:bfsLayer
|
5
|